INKT vs. CYAD, CELU, ATRA, ACET, SGMO, DBVT, OMGA, BLUE, CGTX, and ATHA
Should you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Celyad Oncology (CYAD), Celularity (CELU), Atara Biotherapeutics (ATRA), Adicet Bio (ACET), Sangamo Therapeutics (SGMO), DBV Technologies (DBVT), Omega Therapeutics (OMGA), bluebird bio (BLUE), Cognition Therapeutics (CGTX), and Athira Pharma (ATHA). These companies are all part of the "medical" sector.
Celyad Oncology (NASDAQ:CYAD) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.
2.9% of MiNK Therapeutics shares are held by institutional investors. 0.9% of Celyad Oncology shares are held by insiders. Comparatively, 17.8% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Celyad Oncology received 274 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. However, 68.75% of users gave MiNK Therapeutics an outperform vote while only 67.70% of users gave Celyad Oncology an outperform vote.
In the previous week, MiNK Therapeutics had 3 more articles in the media than Celyad Oncology. MarketBeat recorded 3 mentions for MiNK Therapeutics and 0 mentions for Celyad Oncology. Celyad Oncology's average media sentiment score of 0.40 beat MiNK Therapeutics' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the news media.
Celyad Oncology has higher revenue and earnings than MiNK Therapeutics.
MiNK Therapeutics has a consensus price target of $9.00, suggesting a potential upside of 837.50%. Given Celyad Oncology's higher possible upside, analysts clearly believe MiNK Therapeutics is more favorable than Celyad Oncology.
Summary
MiNK Therapeutics beats Celyad Oncology on 7 of the 11 factors compared between the two stocks.
Get MiNK Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiNK Therapeutics Competitors List
Related Companies and Tools
